Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC

Area of Science:

• Oncology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is a primary liver cancer with limited treatment options.
• Sorafenib is a standard first-line treatment, but resistance and progression are common.
• Regorafenib emerged as a crucial second-line therapy following sorafenib failure.

Purpose of the Study:

• To review the rationale and evidence supporting regorafenib's efficacy in HCC.
• To discuss clinical practice data confirming trial results.
• To explore regorafenib's potential in combination with immunotherapy.

Main Methods:

• Review of clinical trials and real-world evidence on regorafenib in HCC.
• Analysis of regorafenib's mechanism of action, including anti-angiogenic and immunomodulatory effects.
• Exploration of emerging treatment strategies involving regorafenib and immunotherapy.

Main Results:

• Regorafenib demonstrated a survival benefit in patients with unresectable HCC after sorafenib failure.
• Its mechanism involves broad inhibition of tumor growth, angiogenesis, and metastasis.
• Immunomodulatory properties impacting the tumor microenvironment contribute to its efficacy.

Conclusions:

• Regorafenib is an established second-line treatment for advanced HCC post-sorafenib.
• Its multifaceted mechanism supports its clinical benefit.
• Future research should focus on combining regorafenib with immunotherapy for broader patient benefit.